First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer
Lugano, Switzerland, 19 September 2021 – Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative ...
